Organoid-based High-throughput Screening

Introduction: Revolutionary Upgrade of In Vitro Models

Traditional cell lines are high throughput but lackin vivo microenvironment and three-dimensional structure, making it difficult to simulate the real human disease state. Animal models are physiologically relevant but costly, time-consuming, and have significant ethical limitations.Organoidshave emerged to break these limitations. They are formed by self-organizing stem cells or tissue-derived cells into three-dimensional structures,possessing key functional units and spatial structures of the original organs. When organoids are combined withautomated screening platforms, high-throughput screening technology enters a 'more realistic, more precise' new era.

 

I. What is Organoid-based High-throughput Screening?

Organoid-based High-throughput Screening (oHTS) refers to the integration of organoid models with automated screening systems, applied in drug screening, toxicity assessment, target validation, and personalized treatment plan formulation.

Core Characteristics Include:

• Strong physiological relevance: Better reflection of tissue specificity, cellular heterogeneity, and drug response

• Automated operation: Suitable for 96/384 well plate systems, image recognition, and multi-channel plate readers

• Applied tovarious disease models such as tumors, neurological, digestive, and respiratory systems

Biotek Park Biotechnologieshas built a library of various types of organoid models, equipped with complete platforms for drug treatment, labeling, multi-omics detection, and screening analysis, supporting standardized and customized services.

 

II. The Application Value of Organoid HTS in Drug Discovery

1. Early Drug Activity Screening

Organoid-based preliminary screening platforms can more realistically simulate in vivo microenvironments, enhancing screening hit rates and clinical translation potential.

 

2. Personalized Medicine and Drug Resistance Mechanism Research

Building PDOs (Patient-derived Organoids) from patient-derived tissues, conductingdrug sensitivity profiles + genomic analysiscombined interpretation to formulate more effective precision treatment plans for clinical individuals.

 

3. Target Function Verification and Combination Therapy Exploration

Using tools like CRISPR, RNAi for gene editing screening in organoids to explore target action mechanisms and synergistic drug effects.

 

III. Core Technology Workflow of Organoid Screening

1. Organoid Construction

(1) Source: Stem cells, induced pluripotent stem cells (iPSC), patient tumor tissues

(2) Organ Types: Intestine, lung, liver, brain, breast, prostate, pancreas, etc.

(3) Culture Systems: Matrigel embedding, 3D culture, air-liquid interface co-culture, etc.

 

2. High-throughput Processing

(1) Automated liquid handling systems dispensing organoids into 96/384 well plates

(2) Multi-channel drug treatment + dynamic observation (e.g., time gradient/dose response)

(3) Multi-parameter endpoint detection: Morphology, activity, toxicity, fluorescence signals, metabolic products, etc.

 

3. Data Analysis and Mechanism Integration

(1) Image recognition and phenotype clustering

(2) Multi-omics (proteomics, metabolomics, transcriptomics) data integration

(3) Multi-dimensional analysis integrating patient clinical data

 

Biotek Park provides standardized organoid screening workflows and can connect to its independently developed 'multi-omics + pharmacodynamics' data analysis platform, outputting visual result reports to accelerate the transformation of findings.

 

IV. Advantages and Technical Bottlenecks of Organoid HTS

1. Advantages:

• Simulate real tissue structures, improving the 'false positive' and 'false negative' issues in cell models

• Reflect individual differences, especially suitable for personalized medicine research

• Can be used for long-term culture, repeated exposure, and combination therapy evaluation

 

2. Challenges:

• Organoid preparation and amplification cycles are long, with significant batch-to-batch variations

• Uneven volume and asynchronous development affect the standardization of screening

• Automation, AI Image Analysis, and Data Interpretation Still Require Further Integration

 

V. Organoid Screening and Omics Integration: A New Trend in Mechanistic Research

High-throughput organoid screening is not only used to 'identify which drug is effective,' but more importantly to 'reveal why it is effective':

1. Organoids + Proteomics

• Analyze changes in signaling pathways and protein regulation following drug intervention

• Applied in target validation and discovery of drug resistance mechanisms

 

2. Organoids + Metabolomics

• Reveal how drugs affect organoid energy metabolism, lipid synthesis, and redox state

• Especially suitable for metabolism-related models such as liver, intestine, and pancreas

Biotech company Baite Parker has optimized micro-sample processing workflows to conduct highly sensitive mass spectrometry analysis on small organoid samples, filling the technical gap of 'small sample, big data.'

 

High-throughput organoid screening is becoming the critical linkbetween clinical samples, biological mechanisms, and new drug discoveryFrom more realistic physiological simulations to more precise mechanistic interpretations, this technology is reshaping the path and efficiency of drug development. Biotech company Baite Parker integrates an organoid construction platform, high-throughput efficacy screening system, and proteomics/metabolomics analysis capabilities to provide full-process support from model construction, screening execution to mechanistic research for research and industry customers. Contact us to develop drug solutions closer to 'real patients'!

 

Baite Parker Biotech - Characterization of Biological Products, High-Quality Omics Mass Spectrometry Testing Service Provider

 

Related Services: